Balchem Corporation Reports Record Q4 2025 Earnings and Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy BCPC?
Source: seekingalpha
- Record Sales Performance: Balchem achieved consolidated revenues of $264 million in Q4 2025, reflecting a 9.8% year-over-year increase, with Human Nutrition & Health sales reaching $166 million, marking the company's first-ever annual sales exceeding $1 billion, indicating strong market demand and growth potential.
- Enhanced Profitability: The company reported adjusted EBITDA of $68 million for Q4, with a gross margin of 25.8% and net income of $39 million, demonstrating significant improvements in cost control and operational efficiency, further solidifying its market position.
- International Market Expansion: In 2025, over half of Balchem's sales growth originated from markets outside the United States, highlighting the success of its globalization strategy, which is expected to provide robust momentum for continued growth in the future.
- Ongoing Investments and Buybacks: The company invested $43 million in capital projects and repurchased approximately 685,000 shares at an average cost of $158 per share, while also increasing its annual dividend to $0.96, marking the 17th consecutive year of dividend growth, reflecting confidence in its financial health and commitment to shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCPC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCPC
About BCPC
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harvey Partners Acquires New Position in Balchem Corporation
- New Investment Disclosure: Harvey Partners disclosed a new position in Balchem Corporation by acquiring 116,000 shares worth $17.79 million in Q4 2026, indicating confidence in the company's growth potential.
- Holding Proportion Analysis: This acquisition positions Balchem to represent 1.6% of Harvey Partners' reportable AUM of $1.13 billion, highlighting its significance within the fund's portfolio.
- Strong Financial Performance: Balchem achieved record net sales of $1 billion in 2025, an 8.8% increase year-over-year, with net income rising to $154.85 million, up 20.5%, showcasing robust performance in the nutrition and health sectors.
- Solid Financial Position: With a cash balance of $74.6 million and a net debt leverage of only 0.3 times adjusted EBITDA, Balchem's management repurchased $107.6 million in stock in 2025, further boosting investor confidence.
See More
Balchem Corporation Reports Record Q4 2025 Earnings and Growth
- Record Sales Performance: Balchem achieved consolidated revenues of $264 million in Q4 2025, reflecting a 9.8% year-over-year increase, with Human Nutrition & Health sales reaching $166 million, marking the company's first-ever annual sales exceeding $1 billion, indicating strong market demand and growth potential.
- Enhanced Profitability: The company reported adjusted EBITDA of $68 million for Q4, with a gross margin of 25.8% and net income of $39 million, demonstrating significant improvements in cost control and operational efficiency, further solidifying its market position.
- International Market Expansion: In 2025, over half of Balchem's sales growth originated from markets outside the United States, highlighting the success of its globalization strategy, which is expected to provide robust momentum for continued growth in the future.
- Ongoing Investments and Buybacks: The company invested $43 million in capital projects and repurchased approximately 685,000 shares at an average cost of $158 per share, while also increasing its annual dividend to $0.96, marking the 17th consecutive year of dividend growth, reflecting confidence in its financial health and commitment to shareholders.
See More
Balchem (BCPC) Q4 2025 Earnings Call Transcript
See More
Balchem Q4 Earnings Exceed Expectations
- Earnings Beat: Balchem reported a Q4 Non-GAAP EPS of $1.31, exceeding expectations by $0.03, which underscores the company's robust profitability and enhances investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $263.6 million, reflecting a 9.8% year-over-year increase and surpassing expectations by $4.01 million, indicating strong sales performance across all business segments.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at $67.9 million, showcasing the company's success in cost management and operational efficiency, thereby strengthening its competitive position in the market.
- Strong Free Cash Flow: With free cash flow of $51.2 million and cash flows from operations at $67.3 million, Balchem demonstrates solid cash generation capabilities, providing strong support for future investments and shareholder returns.
See More
Balchem Reports Significant Earnings Growth in Q4
- Earnings Growth: Balchem Corp. reported a fourth-quarter profit of $39.22 million, translating to $1.21 per share, which marks a significant increase from last year's $33.58 million and $1.03 per share, indicating strong market performance.
- Adjusted Earnings: Excluding certain items, the company reported adjusted earnings of $42.34 million or $1.31 per share, reflecting positive progress in cost control and efficiency improvements, thereby enhancing profitability.
- Revenue Increase: The company's revenue rose by 9.8% year-over-year to $263.62 million, up from $240 million last year, demonstrating robust market demand and strong product sales performance.
- Market Outlook: With both earnings and revenue growth, Balchem's competitive position in the industry is further strengthened, which is expected to provide a solid financial foundation for future investments and expansions, driving sustained company growth.
See More
Balchem Set to Announce Q4 Earnings on February 20
- Earnings Announcement: Balchem (BCPC) is scheduled to release its Q4 earnings on February 20 before market open, with expectations for continued stable performance.
- Earnings Expectations: Analysts forecast an EPS of $1.28, representing a 13.3% year-over-year increase, indicating ongoing improvements in the company's profitability.
- Revenue Projections: The anticipated revenue for Q4 is $259.59 million, reflecting an 8.2% year-over-year growth, showcasing Balchem's strong performance in market demand and sales growth.
- Historical Performance: Over the past two years, Balchem has exceeded EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating its robust performance stability and market confidence.
See More
Harvey Partners Acquires New Position in Balchem Corporation
- New Investment Disclosure: Harvey Partners disclosed a new position in Balchem Corporation by acquiring 116,000 shares worth $17.79 million in Q4 2026, indicating confidence in the company's growth potential.
- Holding Proportion Analysis: This acquisition positions Balchem to represent 1.6% of Harvey Partners' reportable AUM of $1.13 billion, highlighting its significance within the fund's portfolio.
- Strong Financial Performance: Balchem achieved record net sales of $1 billion in 2025, an 8.8% increase year-over-year, with net income rising to $154.85 million, up 20.5%, showcasing robust performance in the nutrition and health sectors.
- Solid Financial Position: With a cash balance of $74.6 million and a net debt leverage of only 0.3 times adjusted EBITDA, Balchem's management repurchased $107.6 million in stock in 2025, further boosting investor confidence.
See More
Balchem Corporation Reports Record Q4 2025 Earnings and Growth
- Record Sales Performance: Balchem achieved consolidated revenues of $264 million in Q4 2025, reflecting a 9.8% year-over-year increase, with Human Nutrition & Health sales reaching $166 million, marking the company's first-ever annual sales exceeding $1 billion, indicating strong market demand and growth potential.
- Enhanced Profitability: The company reported adjusted EBITDA of $68 million for Q4, with a gross margin of 25.8% and net income of $39 million, demonstrating significant improvements in cost control and operational efficiency, further solidifying its market position.
- International Market Expansion: In 2025, over half of Balchem's sales growth originated from markets outside the United States, highlighting the success of its globalization strategy, which is expected to provide robust momentum for continued growth in the future.
- Ongoing Investments and Buybacks: The company invested $43 million in capital projects and repurchased approximately 685,000 shares at an average cost of $158 per share, while also increasing its annual dividend to $0.96, marking the 17th consecutive year of dividend growth, reflecting confidence in its financial health and commitment to shareholders.
See More
Balchem (BCPC) Q4 2025 Earnings Call Transcript
See More
Balchem Q4 Earnings Exceed Expectations
- Earnings Beat: Balchem reported a Q4 Non-GAAP EPS of $1.31, exceeding expectations by $0.03, which underscores the company's robust profitability and enhances investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $263.6 million, reflecting a 9.8% year-over-year increase and surpassing expectations by $4.01 million, indicating strong sales performance across all business segments.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at $67.9 million, showcasing the company's success in cost management and operational efficiency, thereby strengthening its competitive position in the market.
- Strong Free Cash Flow: With free cash flow of $51.2 million and cash flows from operations at $67.3 million, Balchem demonstrates solid cash generation capabilities, providing strong support for future investments and shareholder returns.
See More
Balchem Reports Significant Earnings Growth in Q4
- Earnings Growth: Balchem Corp. reported a fourth-quarter profit of $39.22 million, translating to $1.21 per share, which marks a significant increase from last year's $33.58 million and $1.03 per share, indicating strong market performance.
- Adjusted Earnings: Excluding certain items, the company reported adjusted earnings of $42.34 million or $1.31 per share, reflecting positive progress in cost control and efficiency improvements, thereby enhancing profitability.
- Revenue Increase: The company's revenue rose by 9.8% year-over-year to $263.62 million, up from $240 million last year, demonstrating robust market demand and strong product sales performance.
- Market Outlook: With both earnings and revenue growth, Balchem's competitive position in the industry is further strengthened, which is expected to provide a solid financial foundation for future investments and expansions, driving sustained company growth.
See More
Balchem Set to Announce Q4 Earnings on February 20
- Earnings Announcement: Balchem (BCPC) is scheduled to release its Q4 earnings on February 20 before market open, with expectations for continued stable performance.
- Earnings Expectations: Analysts forecast an EPS of $1.28, representing a 13.3% year-over-year increase, indicating ongoing improvements in the company's profitability.
- Revenue Projections: The anticipated revenue for Q4 is $259.59 million, reflecting an 8.2% year-over-year growth, showcasing Balchem's strong performance in market demand and sales growth.
- Historical Performance: Over the past two years, Balchem has exceeded EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating its robust performance stability and market confidence.
See More
